76 related articles for article (PubMed ID: 19846308)
1. Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy.
Kollberg G; Holme E
Neuromuscul Disord; 2009 Dec; 19(12):833-6. PubMed ID: 19846308
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestation and a new ISCU mutation in iron-sulphur cluster deficiency myopathy.
Kollberg G; Tulinius M; Melberg A; Darin N; Andersen O; Holmgren D; Oldfors A; Holme E
Brain; 2009 Aug; 132(Pt 8):2170-9. PubMed ID: 19567699
[TBL] [Abstract][Full Text] [Related]
3. Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect.
Olsson A; Lind L; Thornell LE; Holmberg M
Hum Mol Genet; 2008 Jun; 17(11):1666-72. PubMed ID: 18296749
[TBL] [Abstract][Full Text] [Related]
4. Transient restoration of succinate dehydrogenase activity after rhabdomyolysis in iron-sulphur cluster deficiency myopathy.
Kollberg G; Melberg A; Holme E; Oldfors A
Neuromuscul Disord; 2011 Feb; 21(2):115-20. PubMed ID: 21196119
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide corrects splice abnormality in hereditary myopathy with lactic acidosis.
Sanaker PS; Toompuu M; McClorey G; Bindoff LA
Gene; 2012 Feb; 494(2):231-6. PubMed ID: 22155317
[TBL] [Abstract][Full Text] [Related]
6. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
Davis RL; Homer VM; George PM; Brennan SO
Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456
[TBL] [Abstract][Full Text] [Related]
7. Differences in RNA processing underlie the tissue specific phenotype of ISCU myopathy.
Sanaker PS; Toompuu M; Hogan VE; He L; Tzoulis C; Chrzanowska-Lightowlers ZM; Taylor RW; Bindoff LA
Biochim Biophys Acta; 2010 Jun; 1802(6):539-44. PubMed ID: 20206689
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C
Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459
[TBL] [Abstract][Full Text] [Related]
9. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
10. A novel de novo dominant mutation in
Legati A; Reyes A; Ceccatelli Berti C; Stehling O; Marchet S; Lamperti C; Ferrari A; Robinson AJ; Mühlenhoff U; Lill R; Zeviani M; Goffrini P; Ghezzi D
J Med Genet; 2017 Dec; 54(12):815-824. PubMed ID: 29079705
[TBL] [Abstract][Full Text] [Related]
11. The defective splicing caused by the ISCU intron mutation in patients with myopathy with lactic acidosis is repressed by PTBP1 but can be derepressed by IGF2BP1.
Nordin A; Larsson E; Holmberg M
Hum Mutat; 2012 Mar; 33(3):467-70. PubMed ID: 22125086
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders.
Wang Q; Marini JC
J Clin Invest; 1996 Jan; 97(2):448-54. PubMed ID: 8567966
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia.
Vega AI; Pérez-Cerdá C; Desviat LR; Matthijs G; Ugarte M; Pérez B
Hum Mutat; 2009 May; 30(5):795-803. PubMed ID: 19235233
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific splicing of ISCU results in a skeletal muscle phenotype in myopathy with lactic acidosis, while complete loss of ISCU results in early embryonic death in mice.
Nordin A; Larsson E; Thornell LE; Holmberg M
Hum Genet; 2011 Apr; 129(4):371-8. PubMed ID: 21165651
[TBL] [Abstract][Full Text] [Related]
15. The High Level of Aberrant Splicing of ISCU in Slow-Twitch Muscle May Involve the Splicing Factor SRSF3.
Rawcliffe DF; Österman L; Lindsten H; Holmberg M
PLoS One; 2016; 11(10):e0165453. PubMed ID: 27783661
[TBL] [Abstract][Full Text] [Related]
16. Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell lines.
Holmes-Hampton GP; Crooks DR; Haller RG; Guo S; Freier SM; Monia BP; Rouault TA
Hum Mol Genet; 2016 Dec; 25(23):5178-5187. PubMed ID: 28007899
[TBL] [Abstract][Full Text] [Related]
17. Mobilization of the iron centre in IscA for the iron-sulphur cluster assembly in IscU.
Ding B; Smith ES; Ding H
Biochem J; 2005 Aug; 389(Pt 3):797-802. PubMed ID: 15828873
[TBL] [Abstract][Full Text] [Related]
18. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease.
Rodríguez-Pascau L; Coll MJ; Vilageliu L; Grinberg D
Hum Mutat; 2009 Nov; 30(11):E993-E1001. PubMed ID: 19718781
[TBL] [Abstract][Full Text] [Related]
20. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
Pepe CM; Saraco NI; Baquedano MS; Guercio G; Vaiani E; Marino R; Pandey AV; Flück CE; Rivarola MA; Belgorosky A
Clin Endocrinol (Oxf); 2007 Nov; 67(5):698-705. PubMed ID: 17608756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
